9/10
08:00 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.